NetraMark Unveils AI Breakthrough in Parkinson’s Research
Company Announcements

NetraMark Unveils AI Breakthrough in Parkinson’s Research

Netramark Holdings Inc (TSE:AIAI) has released an update.

NetraMark Holdings Inc. has showcased its NetraAI technology’s breakthrough in identifying Parkinson’s disease (PD) subtypes and crucial disease pathways at the AD/PD™ 2024 conference. Leveraging a dataset from the Michael J. Fox Foundation, NetraAI revealed genetic markers and immune system links that could transform PD diagnosis and treatment. These findings not only enhance the understanding of PD but also have implications for other neurodegenerative disorders, potentially accelerating the development of new therapies.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNetraMark Appoints Oncology Expert P.J. Haley to Board
TipRanks Canadian Auto-Generated NewsdeskNetraMark Unveils New Suite to Revolutionize Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskNetraMark’s Q3 Success with AI Clinical Trial Analytics
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App